Breast Cancer Tests Falling Short

A new Dutch study reveals that two-thirds of eligible breast cancer patients aren’t getting crucial genetic tests like MammaPrint and Oncotype DX, which help determine if chemotherapy is truly needed. Though insurance coverage since 2023 boosted usage from 9% to 37%, nearly 1,000 women in 2024 still missed out. When tests were done, high-risk patients overwhelmingly got chemo, while low-risk patients rarely did — but without the test, over half of skipped patients still received chemo unnecessarily. With chemo’s harsh side effects, this gap highlights a critical failure: advanced tools aren’t reaching patients, and doctors aren’t fully leveraging them to deliver personalized, effective care. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/64875b3d5bf7798b